Study TO Prevent Diabetes With Short-term Insulin Glargine Only
Status:
Unknown status
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
- Pre-diabetes is a significant risk factor for the development of type 2 diabetes, as
well as macrovascular and microvascular complication.
- Previous studies show that 50% or more loss in islet B-cell function even in
Pre-diabetes phase. The early insulin therapy in pre-diabetes may be a strategy in
preventing metabolic disorders and cardiovascular disease.
- The objective of this study is to find if an initial insulin glargine intervention in
pre-diabetes (IGT and /or IFG) could be a strategy in preventing type 2 Diabetes.
- Pre-diabetes subjects will receive a insulin glargine therapy with a dosage adjusted to
get FBG ≤ 5.3mmol / L as the goal. Insulin glargine treatment will be maintained for
three months thereafter to find if it can prevent diabetes.